Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 7,739,854
  • Shares Outstanding, K 153,660
  • Annual Sales, $ 745,690 K
  • Annual Income, $ -208,440 K
  • 36-Month Beta 2.23
  • Price/Sales 10.37
  • Price/Cash Flow 0.00
  • Price/Book 6.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.90 +3.01%
on 09/05/17
54.40 -7.41%
on 09/12/17
+0.32 (+0.64%)
since 08/22/17
3-Month
48.90 +3.01%
on 09/05/17
61.31 -17.84%
on 07/05/17
-8.31 (-14.16%)
since 06/22/17
52-Week
41.93 +20.13%
on 10/17/16
63.40 -20.55%
on 06/09/17
-0.63 (-1.24%)
since 09/22/16

Most Recent Stories

More News
Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

JNJ : 131.39 (-0.27%)
REGN : 432.72 (-0.17%)
ALKS : 50.37 (+0.06%)
ALXN : 142.82 (-0.07%)
Patients Switched to Alkermes' ARISTADA(R) Showed Significant Improvement in Schizophrenia Symptoms After Inadequate Response or Intolerance to INVEGA SUSTENNA(R)

Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 4 clinical study of ARISTADA(R) (aripiprazole lauroxil) extended-release injectable suspension for...

ALKS : 50.37 (+0.06%)
Global $4.4 Bn Substance Abuse, Addiction, and Treatment Markets, 2022 - Key Players Pfizer, GlaxoSmithKline, Alkermes, Teva Pharmaceuticals, Reckitt Benckiser, Forest Laboratories

The "Substance Abuse, Addiction, and Treatment: Global Markets" report has been added to Research and Markets' offering.

RBGLY : 18.6700 (+0.92%)
ALKS : 50.37 (+0.06%)
Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

---- Applications Now Open for Submission Through Oct. 6, 2017 --

ALKS : 50.37 (+0.06%)
Alkermes to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its Chief Financial Officer, James Frates, will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare...

MS : 48.22 (-0.08%)
ALKS : 50.37 (+0.06%)
Alkermes to Present Clinical and Real-World Data at Upcoming 30th Annual Psych Congress

---- First Presentation of Recently Completed Phase 4 Study of Patients Switching to ARISTADA(R) From INVEGA SUSTENNA(R) to be Featured --

ALKS : 50.37 (+0.06%)
Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe

Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.

RARE : 52.16 (-0.69%)
IRWD : 15.84 (+2.06%)
VRTX : 151.26 (-0.53%)
ALKS : 50.37 (+0.06%)
AMGN : 185.76 (-0.47%)
ALXN : 142.82 (-0.07%)
BIIB : 318.46 (+1.09%)
Alkermes Initiates Rolling Submission of Depression Drug

Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.

GILD : 83.27 (+0.79%)
REGN : 432.72 (-0.17%)
ALKS : 50.37 (+0.06%)
ADRO : 10.80 (-1.82%)
Donaldson Company Announces New Vice President of Global OEM Sales

Donaldson Company Inc. (NYSE: DCI) today announced that Jacquie Boyer will be joining Donaldson as vice president of global OEM sales, effective August 28, 2017. Boyer will report to Tom...

DCI : 45.43 (+0.53%)
ALKS : 50.37 (+0.06%)
What You See, and What You Get: The Neurology of Perception

While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

SGMO : 13.75 (-3.85%)
SRPT : 45.17 (-4.10%)
NBIX : 58.93 (+0.17%)
ACAD : 37.59 (-0.11%)
ALKS : 50.37 (+0.06%)
BIIB : 318.46 (+1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Support & Resistance

2nd Resistance Point 50.95
1st Resistance Point 50.66
Last Price 50.37
1st Support Level 50.06
2nd Support Level 49.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.